DE69731094T2 - MESYLATDIHYDRATSALZE von 5-(2-(4-(1,2-BENZISOTHIAZOL-3-yl)-1-PIPERAZINYL)-ETHYL)-6-CHLORO-1,3-DIHYDRO-2(1H)-INDOL-2-ON (=ZIPRASIDONE), DESSEN HERSTELLUNG UND VERWENDUNG ALS DOPAMIN-D2-ANTAGONIST - Google Patents
MESYLATDIHYDRATSALZE von 5-(2-(4-(1,2-BENZISOTHIAZOL-3-yl)-1-PIPERAZINYL)-ETHYL)-6-CHLORO-1,3-DIHYDRO-2(1H)-INDOL-2-ON (=ZIPRASIDONE), DESSEN HERSTELLUNG UND VERWENDUNG ALS DOPAMIN-D2-ANTAGONIST Download PDFInfo
- Publication number
- DE69731094T2 DE69731094T2 DE69731094T DE69731094T DE69731094T2 DE 69731094 T2 DE69731094 T2 DE 69731094T2 DE 69731094 T DE69731094 T DE 69731094T DE 69731094 T DE69731094 T DE 69731094T DE 69731094 T2 DE69731094 T2 DE 69731094T2
- Authority
- DE
- Germany
- Prior art keywords
- ziprasidone
- piperazinyl
- benzisothiazol
- dihydro
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title claims description 21
- UAAKJEVCDBPTQS-UHFFFAOYSA-N methanesulfonic acid;dihydrate Chemical class O.O.CS(O)(=O)=O UAAKJEVCDBPTQS-UHFFFAOYSA-N 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 3
- 229960000607 ziprasidone Drugs 0.000 title description 7
- -1 2- (4- (1,2-BENZISOTHIAZOL-3-yl) -1-PIPERAZINYL) -ETHYL Chemical class 0.000 title description 6
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 title 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 claims description 36
- 208000028017 Psychotic disease Diseases 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- WLQZEFFFIUHSJB-UHFFFAOYSA-N ziprasidone mesylate trihydrate Chemical compound O.O.O.CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 WLQZEFFFIUHSJB-UHFFFAOYSA-N 0.000 description 35
- 229960004487 ziprasidone mesylate Drugs 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 10
- 238000000634 powder X-ray diffraction Methods 0.000 description 10
- 239000008227 sterile water for injection Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 229940098779 methanesulfonic acid Drugs 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 150000004683 dihydrates Chemical class 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- ZCBZSCBNOOIHFP-UHFFFAOYSA-N ziprasidone hydrochloride hydrate Chemical compound [H+].O.[Cl-].C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 ZCBZSCBNOOIHFP-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 150000004684 trihydrates Chemical class 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- LKGCPYOBWLSCTK-UHFFFAOYSA-N methanesulfonic acid;trihydrate Chemical compound O.O.O.CS(O)(=O)=O LKGCPYOBWLSCTK-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012066 reaction slurry Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1675796P | 1996-05-07 | 1996-05-07 | |
| US16757P | 1996-05-07 | ||
| PCT/IB1997/000393 WO1997042191A1 (en) | 1996-05-07 | 1997-04-10 | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69731094D1 DE69731094D1 (de) | 2004-11-11 |
| DE69731094T2 true DE69731094T2 (de) | 2006-02-23 |
Family
ID=21778804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69731094T Expired - Lifetime DE69731094T2 (de) | 1996-05-07 | 1997-04-10 | MESYLATDIHYDRATSALZE von 5-(2-(4-(1,2-BENZISOTHIAZOL-3-yl)-1-PIPERAZINYL)-ETHYL)-6-CHLORO-1,3-DIHYDRO-2(1H)-INDOL-2-ON (=ZIPRASIDONE), DESSEN HERSTELLUNG UND VERWENDUNG ALS DOPAMIN-D2-ANTAGONIST |
Country Status (40)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| UA57734C2 (uk) | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| CN1431901A (zh) * | 2000-06-02 | 2003-07-23 | 辉瑞产品公司 | 用于治疗精神病和眼科疾病的s－甲基－二氢一齐拉昔酮 |
| UY27668A1 (es) * | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
| US20040048876A1 (en) * | 2002-02-20 | 2004-03-11 | Pfizer Inc. | Ziprasidone composition and synthetic controls |
| JP2006528676A (ja) * | 2003-05-16 | 2006-12-21 | ファイザー・プロダクツ・インク | 非定形型抗精神病薬と、ｇａｂａ調節薬及び／又は抗痙攣薬の治療上の組合せ |
| US20050043324A1 (en) | 2003-06-03 | 2005-02-24 | Tamas Koltai | Polymorphic forms of ziprasidone HCI and processes for their preparation |
| EP1628973A2 (en) | 2003-10-24 | 2006-03-01 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
| BRPI0510942A (pt) * | 2004-05-11 | 2007-07-17 | Pfizer Prod Inc | combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b |
| CA2467538C (en) | 2004-05-14 | 2010-08-24 | Apotex Pharmachem Inc. | New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same |
| CA2471219A1 (en) | 2004-06-14 | 2005-12-14 | Apotex Pharmachem Inc. | Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) |
| US7777037B2 (en) * | 2004-10-27 | 2010-08-17 | Dr. Reddy's Laboratories Limited | Ziprasidone process |
| KR20130030305A (ko) * | 2004-11-16 | 2013-03-26 | 엘란 파마 인터내셔널 리미티드 | 주사가능한 나노입자형 올란자핀 제형 |
| EP1863806A1 (en) * | 2005-02-11 | 2007-12-12 | Teva Pharmaceutical Industries Ltd | Amorphous ziprasidone mesylate |
| EP1742943A1 (en) * | 2005-02-11 | 2007-01-17 | Teva Pharmaceutical Industries Ltd | Process of preparing ziprasidone mesylate |
| CA2598288A1 (en) * | 2005-03-03 | 2006-09-14 | Elan Pharma International Limited | Nanoparticulate compositions of heterocyclic amide derivatives |
| ITMI20050346A1 (it) | 2005-03-07 | 2006-09-08 | Dipharma Spa | Forma solida di ziprasidone cloridrato |
| CA2500667C (en) | 2005-03-11 | 2013-01-15 | Apotex Pharmachem Inc. | Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions |
| US20060270684A1 (en) * | 2005-03-14 | 2006-11-30 | Judith Aronhime | Crystalline forms of ziprasidone mesylate |
| EP1858892A1 (en) * | 2005-03-14 | 2007-11-28 | Teva Pharmaceutical Industries Ltd | Anhydrous ziprasidone mesylate and a process for its preparation |
| ITMI20052216A1 (it) * | 2005-11-18 | 2007-05-19 | Dipharma Spa | Procedimento per la preparazione di ziprasidone |
| JP2010527925A (ja) * | 2007-05-18 | 2010-08-19 | サイドース・エルエルシー | ジプラシドン製剤 |
| WO2009156889A1 (en) * | 2008-06-25 | 2009-12-30 | Pfizer Inc. | Diaryl compounds and uses thereof |
| WO2012053654A1 (en) * | 2010-10-18 | 2012-04-26 | Dainippon Sumitomo Pharma Co., Ltd. | Sustained-release formulation for injection |
| SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5359068A (en) | 1993-06-28 | 1994-10-25 | Pfizer Inc. | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
| PT904273E (pt) | 1996-05-07 | 2003-06-30 | Pfizer | Sal tri-hidrato de mesilato de 5-{2-¬4-(1,2-benzisotiazol-3-il)-1-piperazinil|-etil}-6-cloro-1,3-di-hidro-2h-indol-2-ona(=ziprasidona) sua preparacao e sua utilizacao como antagonista de dopamina d2 |
-
1997
- 1997-04-01 TW TW086104173A patent/TW491847B/zh not_active IP Right Cessation
- 1997-04-10 ES ES97914520T patent/ES2229342T3/es not_active Expired - Lifetime
- 1997-04-10 CZ CZ19983493A patent/CZ289215B6/cs not_active IP Right Cessation
- 1997-04-10 CA CA002252898A patent/CA2252898C/en not_active Expired - Lifetime
- 1997-04-10 DK DK97914520T patent/DK0918772T3/da active
- 1997-04-10 US US09/180,455 patent/US6245765B1/en not_active Expired - Lifetime
- 1997-04-10 PT PT97914520T patent/PT918772E/pt unknown
- 1997-04-10 PL PL97329884A patent/PL188330B1/pl unknown
- 1997-04-10 BR BR9709889A patent/BR9709889A/pt not_active Application Discontinuation
- 1997-04-10 SI SI9730676T patent/SI0918772T1/xx unknown
- 1997-04-10 EA EA199800912A patent/EA001190B1/ru not_active IP Right Cessation
- 1997-04-10 AU AU21747/97A patent/AU731267B2/en not_active Ceased
- 1997-04-10 UA UA98115905A patent/UA46840C2/uk unknown
- 1997-04-10 KR KR1019980708960A patent/KR100333215B1/ko not_active Expired - Fee Related
- 1997-04-10 IL IL12659197A patent/IL126591A/en not_active IP Right Cessation
- 1997-04-10 EP EP97914520A patent/EP0918772B1/en not_active Expired - Lifetime
- 1997-04-10 CN CN97194244A patent/CN1091769C/zh not_active Expired - Fee Related
- 1997-04-10 WO PCT/IB1997/000393 patent/WO1997042191A1/en active IP Right Grant
- 1997-04-10 JP JP53967297A patent/JP3494659B2/ja not_active Expired - Lifetime
- 1997-04-10 DE DE69731094T patent/DE69731094T2/de not_active Expired - Lifetime
- 1997-04-10 SK SK1508-98A patent/SK282837B6/sk not_active IP Right Cessation
- 1997-04-10 AT AT97914520T patent/ATE278689T1/de not_active IP Right Cessation
- 1997-04-10 TR TR1998/02240T patent/TR199802240T2/xx unknown
- 1997-04-10 NZ NZ332218A patent/NZ332218A/en unknown
- 1997-04-29 GT GT199700052A patent/GT199700052A/es unknown
- 1997-04-29 CO CO97022872A patent/CO4940466A1/es unknown
- 1997-04-30 AP APAP/P/1997/000976A patent/AP765A/en active
- 1997-05-04 EG EG37997A patent/EG24076A/xx active
- 1997-05-05 ID IDP971492A patent/ID16867A/id unknown
- 1997-05-05 AR ARP970101856A patent/AR007004A1/es unknown
- 1997-05-06 DZ DZ970069A patent/DZ2222A1/fr active
- 1997-05-06 TN TNTNSN97074A patent/TNSN97074A1/fr unknown
- 1997-05-06 ZA ZA973876A patent/ZA973876B/xx unknown
- 1997-05-06 MA MA24595A patent/MA24171A1/fr unknown
- 1997-05-06 MY MYPI97001989A patent/MY119997A/en unknown
- 1997-05-07 HR HR970236A patent/HRP970236B1/xx not_active IP Right Cessation
-
1998
- 1998-10-20 IS IS4874A patent/IS2080B/is unknown
- 1998-10-30 OA OA9800206A patent/OA10909A/fr unknown
- 1998-11-03 BG BG102892A patent/BG63544B1/bg unknown
- 1998-11-06 NO NO19985194A patent/NO312514B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69731094T2 (de) | MESYLATDIHYDRATSALZE von 5-(2-(4-(1,2-BENZISOTHIAZOL-3-yl)-1-PIPERAZINYL)-ETHYL)-6-CHLORO-1,3-DIHYDRO-2(1H)-INDOL-2-ON (=ZIPRASIDONE), DESSEN HERSTELLUNG UND VERWENDUNG ALS DOPAMIN-D2-ANTAGONIST | |
| DE69720719T2 (de) | Mesylat des trihydrats des 5-(2-(4-(1,2-benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist | |
| EP1660482B1 (de) | 3-[(2-{ 4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester -methansulfonat und dessen verwendung als arzneimittel | |
| DE60203260T2 (de) | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs | |
| DE69811892T2 (de) | Kristalline form von omeprazol-natriumsalz | |
| DE69736776T2 (de) | 1-(4-piperidyl)-benzimidazole mit neurotropher aktivität | |
| DE60209929T2 (de) | Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen | |
| DE10233500A1 (de) | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel | |
| DE1543715A1 (de) | Verfahren zur Herstellung von basischen Derivaten von Phthalanen und Isochromanen | |
| DE102006054005A1 (de) | Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester | |
| DE69111816T4 (de) | Indolederivate und ihre verwendung als serotonin-antagoniste. | |
| DE60034494T2 (de) | Verwendung von Diphenylmethylpiperazin-Derivaten zur Herstellung eines Medikaments zur Unterdrückung der Proliferation von Fibroblasten | |
| DE69617226T2 (de) | Piperidinderivate. | |
| DE60024947T2 (de) | Chinolin-4-yl derivate und ihre Verwendung als NMDA-Rezeptor Subtyp Blocker | |
| DE69612753T2 (de) | (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, verfahren zu seinerherstellung und dieses enthaltende medizinische zubereitung | |
| DE68918107T2 (de) | Rifapentin-hydrohalide. | |
| DE69815518T2 (de) | S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist | |
| DE60311233T2 (de) | Chinolinderivate | |
| CH637391A5 (de) | Therapeutisch wirksame 3-(1-piperazinyl)-1,2,4-benzotriazine und ihre n-oxide. | |
| DE69715196T2 (de) | Modifizierte form des hydrochlorids der r(-)-n-(4,4-di(-3-methylthien-2-yl)but-3-enyl)-nipecotinsäure | |
| US6962924B2 (en) | Salt and polymorphs of desloratadine hemifumarate | |
| DE60205504T2 (de) | Zitronensäure salz von einer therapeutischen verbindung und deren pharmazeutischen zusammensetzungen | |
| DE2717001A1 (de) | Arzneimittel mit antithrombotischer wirkung | |
| DE2736259C2 (enrdf_load_stackoverflow) | ||
| WO2003029250A1 (de) | Benzisothiazolyl-substituerte aminomethylcromane zur behandlung von erkrankungen des zentralen nervensystems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |